Does Vectura's US deal on respiratory drug mean FDA is softening on approval pathway?
This article was originally published in Scrip
Executive Summary
Vectura has found a replacement US partner for its combination asthma/COPD product, VR315, marking a shift in what has been a major impasse for firms hoping to introduce generic versions of asthma combination products in the US.